Trial Profile

Phase III clinical trial of Ustekinumab biosimilar.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Immunological disorders
Focus Therapeutic Use
Sponsors Bioeq

Most Recent Events

22 May 2020 New trial record
15 May 2020 According to a Formycon media release, Bioeq GmbH is the sponsor of this clinical trial and is also responsible for the study design and clinical operations.
15 May 2020 According to a Formycon media release, Preparations for the start of the phase III clinical trial, which is scheduled for the third quarter of 2020, are continuing as planned.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com